Communiqués Bicycle Therapeutics plc

Actions

BCYC

US0887861088

Temps réel estimé Cboe BZX Autres places de cotation 15:57:34 05/07/2024			Varia. 5j.	Varia. 1 janv.
19,52 ^USD	-0,33 %		-3,16 %	+8,41 %

03/07	Les actions européennes négociées aux États-Unis et les American Depositary Receipts tendent à la hausse dans les échanges de mercredi	MT
24/06	Omega Therapeutics, Inc. nomme Richard N. Kender au conseil d'administration	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bicycle Therapeutics to Participate in Upcoming Investor Conferences	03/06	BU
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting	23/05	BU
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing	23/05	BU
Bicycle Therapeutics : May 2024 Corporate Deck	06/05	PU
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results	02/05	BU
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting	24/04	BU
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	02/04	BU
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024	05/03	BU
Bicycle Therapeutics to Participate in Upcoming Investor Conferences	28/02	BU
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	20/02	BU
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02	BU
Bicycle Therapeutics : 2023 R&D Day Deck	14/12	PU
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day	14/12	BU
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	11/12	AQ
Bicycle Therapeutics to Host R&D Day on December 14	30/11	BU
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day	02/11	BU
Bicycle Therapeutics to Participate in Upcoming Investor Conferences	30/10/23	BU
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer	19/10/23	BU
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director	19/10/23	AQ
Bicycle Therapeutics : BT8009 Regulatory Update \| Bicycle Therapeutics	11/09/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bicycle Therapeutics plc

Actions

BCYC

US0887861088

Communiqués

Filtres